CN114686396A - 一种抗幽门螺杆菌的凝结芽孢杆菌bc99及其应用 - Google Patents
一种抗幽门螺杆菌的凝结芽孢杆菌bc99及其应用 Download PDFInfo
- Publication number
- CN114686396A CN114686396A CN202111587048.3A CN202111587048A CN114686396A CN 114686396 A CN114686396 A CN 114686396A CN 202111587048 A CN202111587048 A CN 202111587048A CN 114686396 A CN114686396 A CN 114686396A
- Authority
- CN
- China
- Prior art keywords
- bacillus coagulans
- helicobacter pylori
- powder
- parts
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000193749 Bacillus coagulans Species 0.000 title claims abstract description 81
- 229940054340 bacillus coagulans Drugs 0.000 title claims abstract description 79
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 62
- 241000590002 Helicobacter pylori Species 0.000 title abstract description 57
- 241000894006 Bacteria Species 0.000 claims abstract description 11
- 208000007882 Gastritis Diseases 0.000 claims abstract description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 5
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 5
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 5
- 244000005700 microbiome Species 0.000 claims abstract description 4
- 208000007107 Stomach Ulcer Diseases 0.000 claims abstract description 3
- 201000005917 gastric ulcer Diseases 0.000 claims abstract description 3
- 230000001580 bacterial effect Effects 0.000 claims description 31
- 239000000843 powder Substances 0.000 claims description 26
- 239000007788 liquid Substances 0.000 claims description 25
- 238000000855 fermentation Methods 0.000 claims description 17
- 230000004151 fermentation Effects 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 7
- 238000004321 preservation Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 229930003270 Vitamin B Natural products 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 235000019156 vitamin B Nutrition 0.000 claims description 4
- 239000011720 vitamin B Substances 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 229940127557 pharmaceutical product Drugs 0.000 claims description 3
- 240000000588 Hericium erinaceus Species 0.000 claims description 2
- 235000007328 Hericium erinaceus Nutrition 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 235000015895 biscuits Nutrition 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 235000012907 honey Nutrition 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 238000009629 microbiological culture Methods 0.000 claims description 2
- 238000010899 nucleation Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002054 inoculum Substances 0.000 claims 1
- 244000052616 bacterial pathogen Species 0.000 abstract description 14
- 108010046334 Urease Proteins 0.000 abstract description 11
- 238000007334 copolymerization reaction Methods 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 238000004220 aggregation Methods 0.000 abstract description 5
- 239000001963 growth medium Substances 0.000 description 29
- 239000000725 suspension Substances 0.000 description 16
- 238000012258 culturing Methods 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 239000008055 phosphate buffer solution Substances 0.000 description 12
- 238000002156 mixing Methods 0.000 description 10
- 239000003242 anti bacterial agent Substances 0.000 description 9
- 229940088710 antibiotic agent Drugs 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000006041 probiotic Substances 0.000 description 9
- 235000018291 probiotics Nutrition 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 239000003833 bile salt Substances 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 238000009630 liquid culture Methods 0.000 description 6
- 230000000529 probiotic effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000001694 spray drying Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000004051 gastric juice Anatomy 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- 206010019375 Helicobacter infections Diseases 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 108010059993 Vancomycin Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011218 seed culture Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229960003165 vancomycin Drugs 0.000 description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 229930183010 Amphotericin Natural products 0.000 description 2
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- 108010040201 Polymyxins Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229940009444 amphotericin Drugs 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940099352 cholate Drugs 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 239000007382 columbia agar Substances 0.000 description 2
- 239000006781 columbia blood agar Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- YLZYSVYZMDJYOT-UHFFFAOYSA-N 2-methoxypyrimidine Chemical class COC1=NC=CC=N1 YLZYSVYZMDJYOT-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 240000005369 Alstonia scholaris Species 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000750379 Erithacus akahige Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000015784 hyperosmotic salinity response Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000002655 kraft paper Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 1
- 229940081192 rifamycins Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
- 229940046307 sodium thioglycolate Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及微生物技术领域,一种抗幽门螺杆菌的凝结芽孢杆菌BC99及其应用。本发明提供的凝结芽孢杆菌BC99具有较强的抑制幽门螺杆菌的能力,在与幽门螺杆菌共培养时,能有效减少幽门螺杆菌的活菌数,降低其生长量,还能显著降低其尿素酶活性。同时,凝结芽孢杆菌BC99具有较强的自聚能力以及与幽门螺杆菌的共聚能力,阻碍病原菌在机体的黏附,体现出凝结芽孢杆菌具有较强的病原菌清除能力。本发明提供凝结芽孢杆菌BC99在制备抗幽门螺杆菌产品以及治疗胃炎、胃溃疡或胃癌的产品上的应用。
Description
技术领域
本发明涉及微生物技术领域,具体涉及一种抗幽门螺杆菌的凝结芽孢杆菌BC99及其应用。
背景技术
幽门螺杆菌是澳大利亚学者罗宾.沃伦(J.Robin,Warren)和巴里马歇尔(Barry,Marshall)在1983年首先分离发现。它是革兰氏阴性杆菌,菌体呈S形或弧形弯曲,一端的鞭毛可以使细菌穿过胃粘膜而定居在胃上皮细胞,能产生大量尿素酶,分解尿素在菌体周围形成弱碱性环境,免受胃酸杀死。幽门螺杆菌在人群感染率高达50%,幽门螺杆菌感染主要发生于胃十二指肠,是引起慢性胃炎、消化性溃疡的主要发病原因,与胃癌发生密切相关。世界卫生组织已把幽门螺杆菌列为胃癌的第一类致癌原。传统治疗幽门螺旋杆菌主要采用铋制剂或质子泵抑制剂加抗生素的三联疗法或四联疗法。而频繁使用抗生素会导致菌群失衡,引起胃肠道不适,腹痛、恶心、呕吐以及腹泻等症状,出现后续治疗依从性差,甚至会产生耐药菌株,病情反复出现。现存的一些根除治疗幽门螺杆菌的方法带来了一些副作用,对人体危害较大,影响了患者的正常生活。因此需要找到一种能有效抑制幽门螺杆菌安全、温和的方法,改善人们的日常生活。
微生态学的兴起,将人们预防、治疗幽门螺杆菌的注意力转向了益生菌,大量研究表明益生菌具有调节肠道菌群平衡,提高机体免疫力,降低抗生素治疗带来的副作用等功能。益生菌可通过代谢产生抑菌物质如细菌素,短链脂肪酸,过氧化氢等来抑制幽门螺杆菌,同时,作为主要益生菌的乳酸菌在代谢过程产生的乳酸有降低幽门螺杆菌尿素酶活性的能力。凝结芽孢杆菌作为益生菌新的研究热点,是一种既能产芽孢又能产乳酸的益生菌,凝结芽孢杆菌还能产生大量的有益代谢产物,如凝结素,短链脂肪酸从而能抑制大肠埃希氏菌,沙门氏菌等常见的肠道致病菌,由于能形成芽孢,耐酸耐胆盐,耐高温高压,因而进入机体后存活率高,更利于在机体发挥有益作用。
发明内容
本发明的目的在于提供一种抗幽门螺杆菌的凝结芽孢杆菌BC99及其应用。
本发明涉及的凝结芽孢杆菌BC99,其微生物保藏号为CGMCC No.21801;分类命名为:凝结芽孢杆菌Bacillus coagulans;保藏时间:2021年02月01日;保藏单位:中国微生物菌种保藏管理委员会普通微生物中心;保藏地址:北京市朝阳区北辰西路1号院3号。
本发明提供的凝结芽孢杆菌BC99具有较强的抑制幽门螺杆菌生长的能力,在与幽门螺杆菌共培养时,能有效减少病原菌的活菌数,明显降低其生长量。
本发明提供的凝结芽孢杆菌BC99能有效降低尿素酶活性,可抵抗幽门螺杆菌感染。
本发明提供的凝结芽孢杆菌BC99具有较强的自聚能力以及与病原菌的共聚能力。自聚能力在24h达到65%以上,与幽门螺杆菌的共聚能力在24h时,达到64%以上。
本发明提供的凝结芽孢杆菌BC99制备成菌粉后的芽孢率可达90%,在中国专利申请202110285874.6中已公开。由于其高芽孢特性,BC99耐胃液耐胆盐能力强,保证其进入胃肠道后存活率高。
本发明提供的凝结芽孢杆菌BC99对青霉素类(青霉素、氨苄西林、苯唑西林和阿莫西林)、头孢菌素类(头孢克洛、头孢曲松和头孢噻吩)、氨基糖苷类(链霉素、庆大霉素和卡那霉素)、大环内脂类(新霉素、红霉素和阿奇霉素)、四环素类(四环素)、糖肽类(万古霉素)、磺胺类(甲氧嘧啶)、喹诺酮类(环丙沙星)、林克胺类(克林霉素)、利福霉素类(利福平)和其他类(新生霉素)10类的20种常见抗生素敏感,安全性高,首次在中国专利申请202110285874.6中公开。
本发明提供的凝结芽孢杆菌BC99能显著降低小鼠胃组织中幽门螺杆菌的含量,从而减少胃粘膜炎症的发生。
本发明提供的凝结芽孢杆菌BC99在制备抗幽门螺杆菌产品以及治疗胃炎、胃溃疡或胃癌的产品上的应用。
所述的产品包含但不限于食品或药品。食品使用形式可包括但不限于糖果,饮料,饼干。药品使用形式可包括但不限于胶囊,片剂,颗粒剂,丸剂等。
根据实施例,所述的产品,包括蛋白粉,也包括胶囊。
本发明提供的凝结芽孢杆菌BC99具有较强的抑制幽门螺杆菌的能力,在与幽门螺杆菌共培养时,能有效减少幽门螺杆菌的活菌数,降低其生长量,还能显著降低尿素酶活性。同时,凝结芽孢杆菌BC99具有较强的自聚能力以及与幽门螺杆菌的共聚能力,阻碍病原菌在机体的黏附,体现出凝结芽孢杆菌具有较强的病原菌清除能力。而且本发明的凝结芽孢杆菌BC99芽孢率高,芽孢状态进入机体后显示出较强的耐胃酸耐胆盐能力。另外所述凝结芽孢杆菌BC99对常见的抗生素敏感,安全性高。
附图说明
图1凝结芽孢杆菌BC99拮抗幽门螺杆菌抑菌圈图。
图2凝结芽孢杆菌BC99降低幽门螺杆菌的尿素酶活性图。
图3凝结芽孢杆菌BC99的自聚能力。
图4凝结芽孢杆菌BC99与病原菌的共聚能力。
图5凝结芽孢杆菌BC99与幽门螺杆菌共培养时幽门螺杆菌的活菌数。
图6凝结芽孢杆菌BC99对胃液和胆盐的耐受能力。
图7凝结芽孢杆菌BC99干预小鼠胃组织中幽门螺杆菌的含量检测。
具体实施方式
下面结合实施例对本发明做进一步详细阐述,但本发明的实施方式不限于此。
本实施例中所用的幽门螺旋杆菌(ATCC 43504)来源于广东微生物菌种保藏中心。本实施例中所用普通培养基常规市场可购买,本实施例中哥伦比亚琼脂购自OXOID公司,BHI固体培养基和液体培养基购自青岛海博生物技术有限公司,无菌脱纤维羊血购自上海源叶生物科技有限公司。
下述实施例所使用的凝结芽孢杆菌培养基的配比为:葡萄糖0.1g,酵母浸粉5g,蛋白胨10g,氯化钠5g,加水定容至1000mL,pH调节至7.0,500mL三角瓶分装,每瓶300mL,按每瓶装量称琼脂粉18g/L于三角瓶中,塞好棉塞,牛皮纸外包扎,121℃灭菌20min。灭菌好的培养基冷却至45~50℃时,倒制平板培养基。
哥伦比亚血平板制备方法:将BHI固体培养基和哥伦比亚琼脂按1:3的比例混合后加入1L水,分装于500ml三角瓶中,121℃灭菌20min,冷却至50~55℃时,加入5%的无菌脱纤维羊血,混合均匀后倒板。
MRS培养基:蛋白胨10g、牛肉膏10g、酵母浸膏5g、葡萄糖20g、K2HPO4 2g、柠檬酸钠2g、Mg SO4·7H2O 0.2g、乙酸钠5.0g、MnSO4·4H2O 0.2g,吐温801m L,1000m L蒸馏水。121℃灭菌20min。
改良MRS培养基:胰蛋白胨10g、牛肉膏10g、酵母浸膏5g、葡萄糖20g、K2HPO42 g、柠檬酸钠2g、Mg SO4·7H2O 0.2g、Mn SO4·4H2O 0.2g,1000m L蒸馏水。121℃灭菌20min。
下述实施例中菌种的活化方法如下:
凝结芽孢杆菌活化:将凝结芽孢杆菌甘油管菌种划线接种至平板培养基中,42℃培养48~72h,挑取单菌落再次划线至斜面培养基42℃培养48~72h,用PBS洗脱收集菌体,调整菌液浓度为108CFU/ml。
鼠李糖乳杆菌LGG的活化:将鼠李糖乳杆菌甘油管划线接种至MRS平板培养基中,37℃培养48~72h,出现单菌落后挑取单菌落接种至改良MRS液体培养基中进行一代活化,37℃培养15~18h,转接二代至改良MRS液体培养基中37℃培养15~18h,得到鼠李糖乳杆菌菌悬液,调整浓度为108CFU/ml
幽门螺杆菌菌种制备:将幽门螺杆菌甘油管划线接种至哥伦比亚血平板中,于37℃三气培养箱中培养3~5天,其中三气培养箱的成分比例为:N2含量85%,CO2含量10%,O2含量5%,待单菌落出现后,挑单菌落再次密集划线至哥伦比亚血平板中,于37℃三气培养箱中培养3~5天,用3~5mlPBS收集平板菌体,调浓度为109CFU/ml,并检测活菌数。
实施例一 凝结芽孢杆菌BC99抑制幽门螺杆菌的能力检测
凝结芽孢杆菌BC99抑制幽门螺杆菌的实验:将哥伦比亚和BHI的混合固体培养基冷却至55℃左右,按100ml培养基加入5ml无菌脱纤维羊血,混合均匀,再取109CFU/ml的幽门螺杆菌菌悬液1ml加入上述混合均匀的培养基中,摇晃均匀,避免产生气泡,使体系病原菌活菌数在107CFU/mL数量级,然后迅速倾注于预先放置牛津杯的平板中,待培养基冷却凝固后,取出牛津杯,于每孔注入200μL的108CFU/ml凝结芽孢杆菌菌悬液,并设鼠李糖乳杆菌LGG为对照,设PBS和改良MRS液体培养基为空白对照,将平皿轻盖后正置于37℃三气培养箱中培养2~3天,并用游标卡尺测量抑菌圈直径,每个菌做三个平行。
表1凝结芽孢杆菌拮抗幽门螺杆菌的抑菌圈直径
如图1和表1所示6株不同的凝结芽孢杆菌对幽门螺杆菌的抑制作用,以LGG为对照,不同菌株表现出对幽门螺杆菌拮抗作用的差异性,其中凝结芽孢杆菌BC99对幽门螺杆菌的抑制能力最强。
实施例二 凝结芽孢杆菌BC99抑制幽门螺杆菌尿素酶活性的检测
将培养好的幽门螺杆菌用PBS重悬两次,用BHI调节幽门螺杆菌浓度为1x108CFU/mL。在96孔板中,取40μL幽门螺杆菌和10μL凝结芽孢杆菌BC99发酵上清液,放入三气培养箱中培养24h。然后取出加入150μL尿素酶测试液,用OD550nm的酶标仪震荡,测定吸光值。空白组为尿素酶指示剂,对照组为BHI培养基。
尿素酶指示剂:0.9%NaCl,20mmo1/L尿素,14ug/mL苯酚红。用HC1调pH至6.8,用分光光度计测OD550nm处的密度值。
结果如图2所示,凝结芽孢杆菌BC99发酵上清液能有效降低幽门螺杆菌尿素酶的活性,从而控制病原菌破坏胃部酸性环境,降低炎症及溃疡的发生。
实施例三 凝结芽孢杆菌BC99的自聚和与幽门螺杆菌的共聚能力
1、自聚能力:将培养好的凝结芽孢杆菌BC99菌液离心,收集菌体,用PBS缓冲液冲洗2次后,再用PBS重悬,调至OD600为0.6。取40mL细胞悬浊液于50mL离心管中,涡旋充分混合后置于37℃条件下孵育,菌悬液孵育2h、5h、21h、24h时后,分别小心吸取上层菌液2.5mL,测定菌悬液在600nm处的吸光值OD,计算菌株自聚力。自聚力%=1-(At/Ao),其中Ao=起始吸光值,At=取样时的吸光值。
2、共聚能力:将凝结芽孢杆菌按3%接种量取菌液接种于MRS液体培养基,37℃培养24h,菌液备用。幽门螺杆菌按5%接种量接种至含10%胎牛血清的BHI液体培养基中,于37℃三气培养箱中培养4天,得到幽门螺杆菌菌液。分别将培养好的凝结芽孢杆菌BC99和幽门螺杆菌离心,收集凝结芽孢杆菌菌体及病原菌菌体,用PBS缓冲液冲洗2次后,再用PBS重悬,调凝结芽孢杆菌BC99的OD600值为0.60,幽门螺杆菌的OD600值为0.4,充分震荡混匀,分别测定初始OD600的值Ax、Ay,凝结芽孢杆菌BC99与幽门螺杆菌各取20mL等体积至50mL离心管中混匀,涡旋震荡20S后37℃静置孵育,菌悬液孵育2h、5h、21h、24h时,分别小心吸取上层液体2.5mL,测定菌悬液在600nm处的吸光值(A),计算菌株与病原菌的共聚力。
共聚力%=[(Ax+Ay)/2-A(x+y)]/[Ax+Ay/2]×100,
其中x和y分别代表两种菌株,(x+y)代表混合物。
结果如图3、图4所示,凝结芽孢杆菌显示出较强的自聚能力,随着时间的延长,自聚能力增强,24h时自聚能力为65%以上。凝结芽孢杆菌与幽门螺杆菌的共聚能力,随着时间的延长,共聚能力增强,24h时共聚能力达到64%。说明凝结芽孢杆菌能够通过共聚方式去除病原菌,更有利发挥益生作用,促进机体的健康水平。
实施例四 凝结芽孢杆菌BC99与幽门螺杆菌的共培养
将活化好的新鲜幽门螺杆菌1x108CFU/mL)重悬在含有10%的胎牛血清BHI液体培养基中,加入10%凝结芽孢杆菌(活菌数1x108CFU/mL),于37℃三气培养箱培养48h,检测活菌数。
LGG活菌数使用MRS培养基检测计数,凝结芽孢杆菌活菌数采用PCA培养基检测计数,幽门螺杆菌采用选择性培养基计数,其中选择性平板培养基为哥伦比亚血琼脂加入1%混合抗生素(多粘菌素B 40mg、甲胺苄啶(TMP)60mg、两性霉素B 40mg、万古霉素50mg,将四种抗生素混合均匀后倒入200mL的无菌带塞容量瓶中,加入双蒸水定容,0.22μm除菌后转移到无菌带盖玻璃瓶中,4℃保存备用)。
结果如图5所示,和幽门螺杆菌纯培养相比,凝结芽孢杆菌BC99在与幽门螺杆菌共培养时,幽门螺杆菌的生长受到抑制,活菌数显著下降。
实施例五 凝结芽孢杆菌BC99的耐受能力测定
模拟胃液:配制0.5%生理盐水,加入0.3%胃蛋白酶,用1mol/L盐酸调节pH至2.5,充分溶解后用0.22μm微孔滤膜过滤除菌备用;
胆盐溶液:在MRS液体培养基中添加0.2%(w/v)的巯基乙酸钠,再加入终浓度为0.3%的胆盐,115℃、灭菌15min备用。
分别取凝结芽孢杆菌BC99的芽孢菌悬液1mL,离心6000rpm 6min,弃上清,加入PBS充分震荡均匀,离心10000rpm,2min小心弃去上清收集菌体。然后加入1mL的模拟胃液中,于37℃培养2.5h,用稀释平板法测定活菌总数(CFU/mL),并以0h测定值作为空白对照,计算存活率。
实验结果如图6显示,在胃液pH 2.5条件下37℃孵育2.5h后,凝结芽孢杆菌BC99活菌数存活率高达93.8%,在胆盐溶液中37℃孵育2.5h后,存活率高达97%。表明凝结芽孢杆菌BC99具有较强的耐受胃液和胆盐的能力,在进入机体后能有效发挥益生功效,调节肠道菌群平衡和机体免疫力。
实施例六 凝结芽孢杆菌BC99抗生素敏感性安全评价
将凝结芽孢杆菌划线接种于琼脂平板上,42℃培养48h后,得到单菌落。挑取单菌落至PBS中制备菌悬液,调整菌悬液浓度为108CFU/mL。取350μL菌悬液,用无菌棉签均匀涂布于整个MRS固体平板,将抗生素药敏试纸片按照一定间距有序置于平板表面37℃,培养适宜时间后观察,用游标卡尺测量抑菌圈直径,结果见表2。
表2凝结芽孢杆菌BC99抗生素敏感性实验安全评价
从表2可以看出,凝结芽孢杆菌BC99对20种抗生素都显示敏感,表明BC99是具有益生功能的安全性菌株。
实施例七 凝结芽孢杆菌BC99菌粉制备
菌种活化:将凝结芽孢杆菌冻干管或甘油管菌种在固体平板上划线,42℃恒温培养箱中培养48~72h,长出大小合适的单菌落。
摇瓶培养:平板上挑取合适的单菌落接入150mL/500mL摇瓶种子培养基中扩大培养,培养温度45℃,摇床转速250rpm,培养至菌液OD 600≥3.0,得到一级种子液。种子培养基配比如下:以重量百分比计为,葡萄糖2.0%、酵母浸粉1.0%、蛋白胨1.0%、MgSO4·7H2O0.03%、MnSO 40.01%、NaCl 0.05%、K2HPO40.1%、FeSO4·7H2 O 0.001%,CaCO30.05%,调节初始pH值为7.0±0.1,115℃灭菌30min。
种子罐扩培:将培养好的一级种子液接入装有种子培养基的种子罐中扩大培养,接种量为5%,培养至菌液OD 600≥6.0,得到二级种子液。
发酵罐发酵:将培养好的二级种子液移种至装有发酵培养基的发酵罐中,二级种子液移种至发酵罐时接种量为5%,发酵24h,得到高浓度凝结芽孢杆菌发酵液。
发酵液离心,喷雾:凝结芽孢杆菌发酵液经离心分离、菌体重悬,得到的浓缩菌悬液进行喷雾干燥,喷雾干燥控制条件为:喷雾干燥塔进风温度为160℃±2℃,出风温度为82℃±2℃,塔内真空度为-0.01MPa~-0.02MPa。收集喷雾干燥后所得的菌粉,即为BC99菌粉。
实施例八 凝结芽孢杆菌BC99干预幽门螺杆菌感染小鼠的实验
1.将凝结芽孢杆菌BC99菌粉用0.85%生理盐水重悬为2x109CFU/mL,灌胃小鼠时使用。
2.将冻存的幽门螺杆菌甘油管菌种在哥伦比亚血平板划线培养,活化两代后在哥伦比亚血平板中培养3天,用PBS洗下菌体,6000r/min离心5min,用生理盐水重悬,调整密度为1x109CFU/mL,立即用于接种动物实验。
3.幽门螺杆菌感染小鼠模型建立选40只C57BL/6雄性小鼠,体重18-20,同室分笼饲养。动物饲养室温度23±2℃,湿度50%±10%,12h/12h昼夜交替,,自由进食及饮水的条件下适应饲养3-5天后随机分组。随机分4组,每组10只,灌胃时,小鼠先禁食12h。第一组为空白组:灌胃量为每天0.5mL/只生理盐水;第二组为幽门螺杆菌感染组:每天灌胃0.5mL5%NaHCO3溶液1h后再接种培养好的具有活力的0.5ml幽门螺杆菌菌液(浓度为1x109CFU/ml),幽门螺杆菌隔天灌胃。第三组为BC99干预组:首先每日1次给每只小鼠灌胃0.5ml BC99菌悬液(浓度为1x109CFU/ml),连续2周后,按第二组的方式灌胃幽门螺杆菌菌液,同时灌胃BC99菌悬液直到检测。第四组为BC99益生菌组,BC99菌液灌胃量为每天浓度为1x109CFU/ml0.5ml的BC99菌悬液,直到检测。
小鼠胃组织中幽门螺杆菌含量的检测:
将小鼠胃组织的匀浆液,通过梯度稀释后,涂布至哥伦比亚血琼脂含1%混合抗生素(多粘菌素B 40mg、甲胺苄啶(TMP)60mg、两性霉素B 40mg、万古霉素50mg,将四种抗生素混合均匀后倒入200mL的无菌带塞容量瓶中,加入双蒸水定容,0.22μm除菌后转移到无菌带盖玻璃瓶中)平板中计数检测,37℃三气培养箱培养72h。
从图7可以看出,幽门螺杆菌感染组小鼠胃组织中幽门螺杆菌含量约在105~106CFU/g,空白组和BC99益生菌组未检测到幽门螺杆菌。BC99干预组,幽门螺杆菌的含量呈明显下降趋势,显示凝结芽孢杆菌在一定程度上抑制了幽门螺杆菌生长,维护机体的正常功能,能有效缓解幽门螺杆菌引起的胃组织炎症。
实施例九 凝结芽孢杆菌BC99在缓解胃炎蛋白粉中的应用
称取蛋白质粉700份,猴头菇粉20份,麦芽糊精60份,维生素B20.5份,维生素B60.5份,BC99菌粉10份混合均匀,再加入10倍重量的水混合均匀,60℃温度下搅拌10分钟,再加入10份蜂蜜搅拌,80℃混匀2小时,然后在75℃条件下烘干研磨成粉,过200目筛,包装即为产品。
实施例十 凝结芽孢杆菌BC99在胶囊产品中的应用
将凝结芽孢杆菌BC99菌液接种种子液培养10h后,按5%接种量接种发酵罐,45℃培养25h后,得到凝结芽孢杆菌BC99发酵液,将发酵液离心、喷雾干燥得到凝结芽孢杆菌BC99菌粉,取适量BC99菌粉与辅料混合装入胶囊中即得BC99胶囊产品。
Claims (6)
1.一种抗幽门螺杆菌的凝结芽孢杆菌BC99和在制备抗幽门螺杆菌产品以及治疗胃炎、胃溃疡或胃癌产品上的应用,凝结芽孢杆菌BC99,其微生物保藏号为CGMCCNo.21801;分类命名为:凝结芽孢杆菌Bacilluscoagulans;保藏时间:2021年02月01日;保藏单位:中国微生物菌种保藏管理委员会普通微生物中心;保藏地址:北京市朝阳区北辰西路1号院3号。
2.根据权利要求1所述的应用,其特征在于,所述的产品包含食品或药品。
3.根据权利要求2所述的应用,其特征在于,所述食品包括糖果,饮料或饼干。
4.根据权利要求2所述的应用,其特征在于,所述药品包括胶囊、片剂、颗粒剂或丸剂。
5.根据权利要求2所述的应用,所述的产品为蛋白粉,其特征在于,称取蛋白质粉700份,猴头菇粉20份,麦芽糊精60份,维生素B20.5份,维生素B60.5份,BC99菌粉10份混合均匀,再加入10倍重量的水混合均匀,60℃温度下搅拌10分钟,再加入10份蜂蜜搅拌,80℃混匀2小时,然后在75℃条件下烘干研磨成粉,过200目筛,包装即为产品。
6.根据权利要求2所述的应用,所述的产品为胶囊,其特征在于,将凝结芽孢杆菌BC99菌液接种种子罐培养10h后,按5%接种量接种发酵罐,45℃培养25h后,得到凝结芽孢杆菌BC99发酵液,将发酵液离心,喷雾干燥得到凝结芽孢杆菌BC99菌粉,取适量BC99菌粉与辅料混合装入胶囊中即得BC99胶囊产品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111587048.3A CN114686396A (zh) | 2021-12-23 | 2021-12-23 | 一种抗幽门螺杆菌的凝结芽孢杆菌bc99及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111587048.3A CN114686396A (zh) | 2021-12-23 | 2021-12-23 | 一种抗幽门螺杆菌的凝结芽孢杆菌bc99及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114686396A true CN114686396A (zh) | 2022-07-01 |
Family
ID=82136216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111587048.3A Pending CN114686396A (zh) | 2021-12-23 | 2021-12-23 | 一种抗幽门螺杆菌的凝结芽孢杆菌bc99及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114686396A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115725461A (zh) * | 2022-11-03 | 2023-03-03 | 东北农业大学 | 一株具有抗幽门螺杆菌作用的解淀粉芽孢杆菌及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2837835A1 (fr) * | 2002-03-29 | 2003-10-03 | Maria Urdaci | Souche bacillus subtilis cu1, son utilisation comme agent immunomodulateur du systeme immunitaire et vaccin recombinant vivant contre h. pylori la contenant |
CN103565848A (zh) * | 2013-03-19 | 2014-02-12 | 青岛东海药业有限公司 | 凝结芽孢杆菌在制备预防和治疗幽门螺杆菌感染制剂中的应用 |
CN105132330A (zh) * | 2015-09-14 | 2015-12-09 | 西南大学 | 一种可预防胃溃疡的发酵乳杆菌Lactobacillus fermentum strain Lee及其用途 |
US20180344754A1 (en) * | 2017-06-06 | 2018-12-06 | Muhammed Majeed | Compositions for management of helicobacter pylori infections |
CN112442457A (zh) * | 2019-08-27 | 2021-03-05 | 大江生医股份有限公司 | 凝结芽孢杆菌或其代谢产物及其胃部保健的用途 |
CN112852679A (zh) * | 2021-03-17 | 2021-05-28 | 武汉微康益生菌研究院有限公司 | 一株益生凝结芽孢杆菌及其应用 |
-
2021
- 2021-12-23 CN CN202111587048.3A patent/CN114686396A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2837835A1 (fr) * | 2002-03-29 | 2003-10-03 | Maria Urdaci | Souche bacillus subtilis cu1, son utilisation comme agent immunomodulateur du systeme immunitaire et vaccin recombinant vivant contre h. pylori la contenant |
CN103565848A (zh) * | 2013-03-19 | 2014-02-12 | 青岛东海药业有限公司 | 凝结芽孢杆菌在制备预防和治疗幽门螺杆菌感染制剂中的应用 |
CN105132330A (zh) * | 2015-09-14 | 2015-12-09 | 西南大学 | 一种可预防胃溃疡的发酵乳杆菌Lactobacillus fermentum strain Lee及其用途 |
US20180344754A1 (en) * | 2017-06-06 | 2018-12-06 | Muhammed Majeed | Compositions for management of helicobacter pylori infections |
CN112442457A (zh) * | 2019-08-27 | 2021-03-05 | 大江生医股份有限公司 | 凝结芽孢杆菌或其代谢产物及其胃部保健的用途 |
CN112852679A (zh) * | 2021-03-17 | 2021-05-28 | 武汉微康益生菌研究院有限公司 | 一株益生凝结芽孢杆菌及其应用 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115725461A (zh) * | 2022-11-03 | 2023-03-03 | 东北农业大学 | 一株具有抗幽门螺杆菌作用的解淀粉芽孢杆菌及其应用 |
CN115725461B (zh) * | 2022-11-03 | 2024-03-19 | 东北农业大学 | 一株具有抗幽门螺杆菌作用的解淀粉芽孢杆菌及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8846027B2 (en) | Compositions for the vaginal and oral administration of Lactobacillus and uses thereof | |
CN100386427C (zh) | 双歧杆菌和含有它们的制品 | |
JP5830084B2 (ja) | 胃腸状態の予防及び処置にバチルス・ズブチリス菌株を使用する方法 | |
US20140227227A1 (en) | Use of roseburia in the prevention and treatment for obesity related diseases | |
CN110141585A (zh) | 一种用于调节肠道菌群的复合益生菌发酵菌剂及其制备方法 | |
CA2535892A1 (en) | A stable liquid probiotic composition, preparation and applications thereof | |
JP2001258549A (ja) | ヘリコバクターピロリに対して抗菌活性を有するラクトバシルスアシドフィルスhy2177、ラクトバシルスカセイhy2743及びそれらを用いた乳酸菌製剤と発酵乳 | |
CN114958650A (zh) | 一种防治幽门螺杆菌感染的副干酪乳杆菌及其组合物与应用 | |
CN113005067B (zh) | 多功能复合益生菌制剂及其制备方法 | |
AU3472693A (en) | Probiotic for control of salmonella | |
CN113577218A (zh) | 一种抑制幽门螺旋杆菌的灭活益生菌中药组合物及其制备方法和应用 | |
CN114540243A (zh) | 一种能够预防和或治疗幽门螺杆菌感染的鼠李糖乳杆菌及其应用 | |
KR101000364B1 (ko) | 생존율 증강용 이중 코팅 방법 | |
CN115153026A (zh) | 鼠李糖乳杆菌菌株LRa05在制备抑制幽门螺杆菌和/或变异链球菌制品方面的用途 | |
CN114686396A (zh) | 一种抗幽门螺杆菌的凝结芽孢杆菌bc99及其应用 | |
Lazarenko et al. | Imunobiotics are the novel biotech drugs with antibacterial and immunomodulatory properties | |
AU2011212513B2 (en) | Improvement of immunomodulatory properties of Lactobacillus strains | |
CN111685255B (zh) | 一种增强免疫功能的益生菌固体饮料及其制备方法 | |
CN112940983A (zh) | 一种能增加抗幽门螺杆菌效果的植物乳杆菌制剂及其制备方法 | |
CN111345473A (zh) | 一种含卵黄抗体IgY的益生菌组合物及应用制剂 | |
CN115119940A (zh) | 嗜酸乳杆菌LA85和乳双歧杆菌BLa80在抑制幽门螺旋杆菌上的应用 | |
JP4509250B2 (ja) | Helicobacterpylori除菌性医薬品 | |
EP1796700B1 (en) | Eukaryotic based synergistic formulation for gastro-intestinal disorders | |
CN116103197B (zh) | 一种对幽门螺旋杆菌有抑制作用的嗜热链球菌及其应用 | |
CN113577112B (zh) | 一种防治禽沙门氏菌病的药物组合物及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |